Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG, Khalili M, Fontana RJ, Sterling RK, Terrault N, Feld JJ, Di Bisceglie AM, Lau DTY, Hassan M, Janssen HLA; Hepatitis B Research Network (HBRN). Lok AS, et al. Among authors: lalama cm. Hepatology. 2021 Jun;73(6):2124-2140. doi: 10.1002/hep.31554. Epub 2021 May 21. Hepatology. 2021. PMID: 32936969 Free PMC article.
Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.
Bedimo RJ, Mar H, Bosch RJ, Drechsler H, Cyktor JC, Macatangay BJC, Lalama C, Rinaldo C Jr, Collier A, Godfrey C, Hogg E, Hensel C, Eron JJ, Mcmahon DK, Mellors JW, Tebas P, Gandhi RT; A5321 Study Team. Bedimo RJ, et al. J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):e27-e31. doi: 10.1097/QAI.0000000000002124. J Acquir Immune Defic Syndr. 2019. PMID: 31335587 Free PMC article.
Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.
Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT; ACTG 5321 Team. Keating SM, et al. Among authors: lalama cm. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):594-599. doi: 10.1097/QAI.0000000000002080. J Acquir Immune Defic Syndr. 2019. PMID: 31045647 Free PMC article.
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. Wilkin TJ, et al. Among authors: lalama cm. J Infect Dis. 2012 Aug 15;206(4):534-42. doi: 10.1093/infdis/jis376. Epub 2012 Jun 27. J Infect Dis. 2012. PMID: 22740718 Free PMC article. Clinical Trial.
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR, Hilldorfer BB, Lalama CM, McKinnon JE, Coombs RW, Tenorio AR, Fox L, Gandhi RT, Ribaudo H, Currier JS, Gulick RM, Wilkin TJ, Mellors JW. Cillo AR, et al. Among authors: lalama cm. AIDS. 2015 Oct 23;29(16):2121-9. doi: 10.1097/QAD.0000000000000810. AIDS. 2015. PMID: 26544577 Free PMC article. Clinical Trial.
Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.
Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW; ACTG A5321 Team. Gandhi RT, et al. Among authors: lalama cm. PLoS Pathog. 2017 Apr 20;13(4):e1006285. doi: 10.1371/journal.ppat.1006285. eCollection 2017 Apr. PLoS Pathog. 2017. PMID: 28426825 Free PMC article.
43 results